{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:06:07Z","timestamp":1768442767454,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["glob health res policy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malaria elimination in the Asia\u2013Pacific region has stalled in recent years, partially due to disrupted access to antimalarial drugs during public health emergencies. This study aims to explore the access to antimalarial drugs and its contextual factors in health emergencies based on investigation into six Asia\u2013Pacific countries during the COVID-19, including Bangladesh, India, Indonesia, Pakistan, Thailand and Viet Nam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extracted the quarterly data for 37 antimalarial drugs using the IQVIA database from the first quarter in 2020 to the second quarter in 2022. We used standard units (SU) sold per 1000 incident cases and US dollars per 1000 incident cases to evaluate consumption (accessibility). Changes in consumption were estimated using compound annual growth rate (CAGR). Associations between consumption and country\u2019s socioeconomic, health performance and product supplier indicators were measured using least squares (pooled) panel data regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Available antimalarial drugs ranged from 31 in India, and 6 in Bangladesh and Viet Nam. The predominant medicine category in all six countries was quinine and other quinoline derivatives. The highest level of average consumption per 1000 incident cases was observed in Viet Nam (2004141.9 SU per 1000 incident cases). The country presenting the lowest level of accessibility was Indonesia (3668 SU per 1000 incident cases). Between 2020 and 2022, all countries except Viet Nam presented a decreased consumption per 1000 incident cases, with CAGRs being respectively\u2009\u2212\u200915.11% in Bangladesh,\u2009\u2212\u20093.66% in India,\u2009\u2212\u200923.56% in Indonesia,\u2009\u2212\u200913.28% in Pakistan and\u2009\u2212\u200912.07% in Thailand. Increased Log consumption per 1000 incident cases was associated with higher proportion of health expenditure out of total government expenditure (coefficient 1.84, 95% confidence interval 0.47\u20133.21) and higher proportion of local supply (coefficient 0.43, 95% confidence interval 0.06\u20130.80).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There has been a disruption in the access to antimalarial drugs during the COVID-19 pandemic in the Asia\u2013Pacific region, and the predominant available medicines were those with documented resistance. Greater priority should be given to drug innovation aimed at improving availability, along with strengthening health systems and local production to maintain accessibility to these drugs, especially during health emergencies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41256-025-00454-6","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T11:06:27Z","timestamp":1765796787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Access to antimalarial drugs in the Asia\u2013Pacific region during health emergency: a multinational cross-sectional investigation between 2020 and 2022"],"prefix":"10.1016","volume":"10","author":[{"given":"Yinuo","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3660-1276","authenticated-orcid":false,"given":"Yangmu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"454_CR1","doi-asserted-by":"publisher","DOI":"10.30875\/9789287076717","volume-title":"World Malaria Report 2024: Addressing Inequity in the Global Malaria Response","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. World Malaria Report 2024: Addressing Inequity in the Global Malaria Response. Geneva: World Health Organization; 2024."},{"key":"454_CR2","volume-title":"World Malaria Report 2022","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. World Malaria Report 2022. Geneva: World Health Organization; 2022."},{"key":"454_CR3","volume-title":"World Malaria Report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. World Malaria Report 2023. Geneva: World Health Organization; 2023."},{"issue":"1","key":"454_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41256-023-00306-1","volume":"8","author":"Q Liu","year":"2023","unstructured":"Liu Q, Yan W, Qin C, Du M, Wang Y, Liu M, et al. Incidence and mortality trends of neglected tropical diseases and malaria in China and Asean countries from 1990 to 2019 and its association with the socio-demographic index. Glob Health Res Policy. 2023;8(1):22.","journal-title":"Glob Health Res Policy"},{"issue":"4","key":"454_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14737167.2020.1782196","volume":"20","author":"S Shah","year":"2020","unstructured":"Shah S, Abbas G, Riaz N, Aneesur R, Hanif M, Rasool MF. Burden of communicable diseases and cost of illness: Asia Pacific Region. Exp Rev Pharmacoecon Outcomes Res. 2020;20(4):343\u201354.","journal-title":"Exp Rev Pharmacoecon Outcomes Res"},{"key":"454_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.12688\/wellcomeopenres.14769.1","volume":"4","author":"R Shretta","year":"2019","unstructured":"Shretta R, Silal SP, Celhay OJ, Gran Mercado CE, Kyaw SS, Avancena A, et al. Malaria elimination transmission and costing in the Asia-Pacific: developing an investment case. Wellcome Open Res. 2019;4:60.","journal-title":"Wellcome Open Res"},{"key":"454_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2724-z","author":"EG Tse","year":"2019","unstructured":"Tse EG, Korsik M, Todd MH. The past, present and future of anti-malarial medicines. Malar J. 2019. https:\/\/doi.org\/10.1186\/s12936-019-2724-z.","journal-title":"Malar J"},{"issue":"5874","key":"454_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.1155165","volume":"320","author":"NJ White","year":"2008","unstructured":"White NJ. Qinghaosu (Artemisinin): the price of success. Science. 2008;320(5874):330\u20134.","journal-title":"Science"},{"issue":"10","key":"454_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","volume":"22","author":"JL Siqueira-Neto","year":"2023","unstructured":"Siqueira-Neto JL, Wicht KJ, Chibale K, Burrows JN, Fidock DA, Winzeler EA. Antimalarial drug discovery: progress and approaches. Nat Rev Drug Discov. 2023;22(10):807\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"454_CR10","volume-title":"Who guidelines for malaria","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Who guidelines for malaria. Geneva: World Health Organization; 2023."},{"issue":"4","key":"454_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5694\/mja2.52398","volume":"221","author":"FJI Fowkes","year":"2024","unstructured":"Fowkes FJI, Robinson LJ, Simpson JA, Thriemer K, Laman M, Oo WH. The challenges of malaria elimination in the Asia-Pacific region. Med J Aust. 2024;221(4):182\u20135.","journal-title":"Med J Aust"},{"key":"454_CR12","volume-title":"Fourth Round of the Global Pulse Survey on Continuity of Essential Health Services During the Covid-19 Pandemic: November 2022\u2013January 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Fourth Round of the Global Pulse Survey on Continuity of Essential Health Services During the Covid-19 Pandemic: November 2022\u2013January 2023. Geneva: World Health Organization; 2023."},{"key":"454_CR13","unstructured":"World Health Organization. Disease Outbreak News: Malaria \u2013 Pakistan. https:\/\/www.who.int\/Emergencies\/Disease-Outbreak-News\/Item\/2022-Don413. Accessed 17 Oct 2024."},{"issue":"12","key":"454_CR14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S1473-3099(06)70655-7","volume":"6","author":"DG Lalloo","year":"2006","unstructured":"Lalloo DG, Olukoya P, Olliaro P. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. Lancet Infect Dis. 2006;6(12):780\u201393.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"454_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2022.12366","volume":"328","author":"JP Daily","year":"2022","unstructured":"Daily JP, Minuti A, Khan N. Diagnosis, treatment, and prevention of malaria in the Us: a review. JAMA. 2022;328(5):460\u201371.","journal-title":"JAMA"},{"key":"454_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027503","author":"M Saito","year":"2019","unstructured":"Saito M, Mansoor R, Kennon K, McGready R, Nosten F, Gu\u00e9rin PJ, et al. Efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a protocol for systematic review and individual patient data (Ipd) meta-analysis. BMJ Open. 2019. https:\/\/doi.org\/10.1136\/bmjopen-2018-027503.","journal-title":"BMJ Open"},{"key":"454_CR17","unstructured":"IQVIA. MIDAS Database. https:\/\/www.iqvia.com\/solutions\/commercialization\/brand-strategy-and-management\/market-measurement\/midas. Accessed 17 Jun 2023."},{"issue":"1","key":"454_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1473-3099(20)30332-7","volume":"21","author":"EY Klein","year":"2021","unstructured":"Klein EY, Milkowska-Shibata M, Tseng KK, Sharland M, Gandra S, Pulcini C, et al. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000\u201315: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2021;21(1):107\u201315.","journal-title":"Lancet Infect Dis"},{"key":"454_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101848","author":"A Nandi","year":"2023","unstructured":"Nandi A, Pecetta S, Bloom DE. Global antibiotic use during the Covid-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020\u20132022. eClinMed. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101848.","journal-title":"eClinMed"},{"key":"454_CR20","doi-asserted-by":"crossref","unstructured":"Jayawardana S, Forman R, Johnston-Webber C, Campbell A, Berterame S, de Joncheere C, et al. Global consumption of prescription opioid analgesics between 2009\u20132019: a country-level observational study. eClinicalMedicine. 2021;42.","DOI":"10.1016\/j.eclinm.2021.101198"},{"key":"454_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12010033","author":"J Ma","year":"2023","unstructured":"Ma J, Sun Y, Cui Y, Dong J, Huang Y. Access to Dtp-based combination vaccines in Asia-Pacific countries between 2019 and 2022. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines12010033.","journal-title":"Vaccines"},{"key":"454_CR22","volume":"26","author":"X Tong","year":"2022","unstructured":"Tong X, Li X, Pratt NL, Hillen JB, Stanford T, Ward M, et al. Monoclonal antibodies and Fc-fusion protein biologic medicines: a multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020. Lancet Reg Health West Pac. 2022;26:100506.","journal-title":"Lancet Reg Health West Pac"},{"key":"454_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.12688\/wellcomeopenres.15467.3","volume":"4","author":"RM Carrillo-Larco","year":"2019","unstructured":"Carrillo-Larco RM, Altez-Fernandez C, Ugarte-Gil C. Is diabetes associated with malaria and malaria severity? A systematic review of observational studies. Wellcome Open Res. 2019;4:136.","journal-title":"Wellcome Open Res"},{"key":"454_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.2817","author":"A Holm","year":"2020","unstructured":"Holm A, Gomes LC, Biering-Soerensen T, Silvestre O, Brainin P. Malaria and cardiovascular disease: a systematic review. Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.2817.","journal-title":"Eur Heart J"},{"issue":"1","key":"454_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12199-017-0682-z","volume":"22","author":"K Takashima","year":"2017","unstructured":"Takashima K, Wada K, Tra TT, Smith DR. A review of Vietnam\u2019s healthcare reform through the direction of healthcare activities (Doha). Environ Health Prev Med. 2017;22(1):74.","journal-title":"Environ Health Prev Med"},{"issue":"14","key":"454_CR26","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1056\/NEJMp1410425","volume":"372","author":"D Blumenthal","year":"2015","unstructured":"Blumenthal D, Hsiao W. Lessons from the east\u2013China\u2019s rapidly evolving health care system. N Engl J Med. 2015;372(14):1281\u20135.","journal-title":"N Engl J Med"},{"key":"454_CR27","unstructured":"World Health Organization. Regional Office for the Western P. The Kingdom of Thailand Health System Review. https:\/\/iris.who.int\/Handle\/10665\/208216. Accessed 3 Feb 2025."},{"key":"454_CR28","unstructured":"World Health Organization. The Republic of Indonesia Health System Review. 2017. https:\/\/apps.who.int\/Iris\/Handle\/10665\/254716. Accessed 3 Feb 2025."},{"issue":"9","key":"454_CR29","first-page":"e44641","volume":"15","author":"SJ Khan","year":"2023","unstructured":"Khan SJ, Asif M, Aslam S, Khan WJ, Hamza SA. Pakistan\u2019s healthcare system: a review of major challenges and the first comprehensive universal health coverage initiative. Cureus. 2023;15(9):e44641.","journal-title":"Cureus"},{"issue":"7","key":"454_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14737167.2022.2086122","volume":"22","author":"B Sapkota","year":"2022","unstructured":"Sapkota B, Palaian S, Shrestha S, Ozaki A, Mohamed Ibrahim MI, Jakovljevic M. Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region. Expert Rev Pharmacoecon Outcomes Res. 2022;22(7):1043\u201350.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"454_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1475-2875-10-144","volume":"10","author":"J Achan","year":"2011","unstructured":"Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144.","journal-title":"Malar J"},{"issue":"8","key":"454_CR32","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nm.4381","volume":"23","author":"B Blasco","year":"2017","unstructured":"Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23(8):917\u201328.","journal-title":"Nat Med"},{"issue":"1","key":"454_CR33","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1038\/s41467-020-17781-6","volume":"11","author":"SH Shafik","year":"2020","unstructured":"Shafik SH, Cobbold SA, Barkat K, Richards SN, Lancaster NS, Llin\u00e1s M, et al. The natural function of the malaria parasite\u2019s chloroquine resistance transporter. Nat Commun. 2020;11(1):3922.","journal-title":"Nat Commun"},{"key":"454_CR34","first-page":"9720823","volume":"2018","author":"C Dijanic","year":"2018","unstructured":"Dijanic C, Nickerson J, Shakya S, Dijanic A, Fabbri M. Relapsing malaria: a case report of primaquine resistance. Case Rep Infect Dis. 2018;2018:9720823.","journal-title":"Case Rep Infect Dis"},{"key":"454_CR35","volume-title":"Artemisinin resistance and artemisinin-based combination therapy efficacy","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Artemisinin resistance and artemisinin-based combination therapy efficacy. Geneva: World Health Organization; 2018."},{"issue":"6","key":"454_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(21)00748-9","volume":"22","author":"I Chen","year":"2022","unstructured":"Chen I, Hsiang MS. Triple artemisinin-based combination therapies for malaria: a timely solution to counter antimalarial drug resistance. Lancet Infect Dis. 2022;22(6):751\u20133.","journal-title":"Lancet Infect Dis"},{"key":"454_CR37","unstructured":"Lahange S, Sharad D, Porte M, Archana D, Nivrutti B. Traditional medicine used for Malaria in India. 2016:39\u201346."},{"issue":"1","key":"454_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12936-023-04606-2","volume":"22","author":"DE Mbassi","year":"2023","unstructured":"Mbassi DE, Pfaffendorf C, Mombo-Ngoma G, Kreuels B, Ramharter M. Real-life effectiveness of anti-malarial treatment regimens: what are we aiming for? Malar J. 2023;22(1):189.","journal-title":"Malar J"},{"issue":"1","key":"454_CR39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12936-021-03821-z","volume":"20","author":"NJ White","year":"2021","unstructured":"White NJ, Nosten FH. Sercap: is the perfect the enemy of the good? Malar J. 2021;20(1):281.","journal-title":"Malar J"},{"key":"454_CR40","volume-title":"Pulse Survey on Continuity of Essential Health Services During the Covid-19 Pandemic","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Pulse Survey on Continuity of Essential Health Services During the Covid-19 Pandemic. Geneva: World Health Organization; 2023."},{"issue":"1","key":"454_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1473-3099(20)30700-3","volume":"21","author":"DJ Weiss","year":"2021","unstructured":"Weiss DJ, Bertozzi-Villa A, Rumisha SF, Amratia P, Arambepola R, Battle KE, et al. Indirect effects of the Covid-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis. Lancet Infect Dis. 2021;21(1):59\u201369.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"454_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1071\/AH17031","volume":"43","author":"D Gleeson","year":"2019","unstructured":"Gleeson D, Townsend B, Lopert R, Lexchin J, Moir H. Financial costs associated with monopolies on biologic medicines in Australia. Aust Health Rev. 2019;43(1):36\u201342.","journal-title":"Aust Health Rev"},{"issue":"1","key":"454_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s41256-023-00319-w","volume":"8","author":"XX Zhang","year":"2023","unstructured":"Zhang XX, Jin YZ, Lu YH, Huang LL, Wu CX, Lv S, et al. Infectious disease control: from health security strengthening to health systems improvement at global level. Glob Health Res Policy. 2023;8(1):38.","journal-title":"Glob Health Res Policy"},{"issue":"8","key":"454_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003443","volume":"4","author":"H Nguyen","year":"2024","unstructured":"Nguyen H, Jongdeepaisal M, Tuan DA, Khonputsa P, Ngo T, Pell C, et al. Sustaining village malaria worker programmes with expanded roles: perspectives of communities, healthcare workers, policymakers, and implementers in Vietnam. PLoS Glob Public Health. 2024;4(8):e0003443.","journal-title":"PLoS Glob Public Health"},{"issue":"1","key":"454_CR45","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1186\/s12889-021-11602-1","volume":"21","author":"M Ipa","year":"2021","unstructured":"Ipa M, Laksono AD, Astuti EP, Prasetyowati H, Pradani FY, Hendri J, et al. Sub-national disparities in accessing anti-malarial drug treatment in eastern Indonesia. BMC Public Health. 2021;21(1):1548.","journal-title":"BMC Public Health"},{"key":"454_CR46","unstructured":"World Health Organization. World Health Assembly Resolution Wha74.6 Strengthening Local Production of Medicines and Other Health Technologies to Improve Access. Geneva: World Health Organization. 2021."},{"key":"454_CR47","first-page":"39","volume-title":"Rethinking global and local manufacturing of medical products after covid-19, in vaccines, medicines and covid-19: how can who be given a stronger voice?","author":"G Vel\u00e1squez","year":"2022","unstructured":"Vel\u00e1squez G. Rethinking global and local manufacturing of medical products after covid-19, in vaccines, medicines and covid-19: how can who be given a stronger voice? Cham: Springer; 2022. p. 39\u201358."},{"issue":"1","key":"454_CR48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12063-021-00179-y","volume":"15","author":"Z Yu","year":"2022","unstructured":"Yu Z, Razzaq A, Rehman A, Shah A, Jameel K, Mor RS. Disruption in global supply chain and socio-economic shocks: a lesson from Covid-19 for sustainable production and consumption. Oper Manag Res. 2022;15(1):233\u201348.","journal-title":"Oper Manag Res"},{"key":"454_CR49","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12936-016-1422-3","volume":"15","author":"Y Huang","year":"2016","unstructured":"Huang Y, Li H, Peng D, Wang Y, Ren Q, Guo Y. The production and exportation of Artemisinin-derived drugs in China: current status and existing challenges. Malar J. 2016;15:365.","journal-title":"Malar J"},{"issue":"1","key":"454_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40249-022-00970-4","volume":"11","author":"Y Xie","year":"2022","unstructured":"Xie Y, Wang J, Sun Y, Ke X, Xie Z, Cao J, et al. Priorities of China\u2019s participation in global malaria elimination: the perspective of malaria endemic countries. Infect Dis Pov. 2022;11(1):46.","journal-title":"Infect Dis Pov"}],"container-title":["Global Health Research and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41256-025-00454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41256-025-00454-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41256-025-00454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:27:18Z","timestamp":1768404438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41256-025-00454-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1186\/s41256-025-00454-6","relation":{},"ISSN":["2397-0642"],"issn-type":[{"value":"2397-0642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Study doesn\u2019t involve human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}